2019 Thales Access Management Index Finds Almost Half of Businesses Believe Cloud Apps Make Them Target for Cyber-Attacks
According to new research from Thales, almost half (49%) of businesses believe cloud apps make them a target for cyber-attacks. Surveying 1,050 IT decision makers globally, Thales’ 2019 Access Management Index 1 revealed that cloud applications (49%) are listed in the top three reasons an organization might be attacked, just behind unprotected infrastructure such as IoT devices (54%) and web portals (50%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190708005443/en/
2019 Access Management Index (Photo: Thales)
With cloud applications now a crucial part of day-to-day business operations, the majority (97%) of IT leaders believe that cloud access management is necessary to continue their cloud adoption. However, despite four in 10 (38%) organizations appointing a CISO due to concerns over data breaches in the past 12 months, and 79% of IT decision makers stating that CISOs are responsible for selecting the solutions their company has in place, just one in 10 (14%) are given the final decision on cloud access management. In fact, companies are more likely to put their faith in a traditional IT role, CIOs (48%) when dealing with this, suggesting a disconnection between the decision-making and implementation surrounding cloud security.
“Thales protects our customers’ business by enabling them to securely access and use cloud applications. The 2019 Thales Access Management Index findings clearly show concerns surrounding cyber-attacks when deploying cloud applications. Trusted accesss to the cloud is key to our customers’ digital transformation, but without adequate investment in a dedicated CISO office, organizations will lack the leadership required to implement the correct security strategy or solutions to keep them secure in the cloud,” says Tina Stewart, vice president market strategy for cloud protection and licensing activity at Thales.
Breaches bringing changes
Positively, the growing awareness of consumer data breaches has led to organizations taking action; almost all (94%) have changed their security policies around access management in the last 12 months. What’s more, the biggest areas of changes have focused around: staff training on security and access management (52%); increasing spend on access management (45%), and access management becoming a board priority (44%).
Obstacles blocking access management
In spite of the updates to security policies, the majority of IT leaders (95%) believe ineffective cloud access management is still a concern for their organization. In fact, their biggest concerns are its impact on security (48%), IT staffs’ time (44%) and on operational overheads and IT costs (43%). Worse, when it comes to implementing access management solutions, they cited costs (40%), human error (39%) and difficulty integrating them (36%) as the biggest obstacles.
When it comes to cloud solutions, three-quarters (75%) of organizations already rely on access management to secure their external users’ logins to online corporate resources. In particular, two-factor authentication is the most likely (58%) tool to be seen as effective at protecting cloud and web-based apps, followed by smart single sign-on (49%) and biometric authentication (47%).
Stewart concludes: “While organizations are getting to grips with access management solutions, IT and business decision makers must ensure they understand the risks to their cloud solutions in order to implement the relevant ones. These solutions must be perimeter-free, compatible with a zero-trust model and flexible and adaptive in order to make the most of the latest technologies such as Smart SSO. Without effective access management tools in place organizations face a higher risk of breaches, a lack of visibility and incur extra costs from poorly optimized cloud.”
For more information, attend our Global Trends in Cloud Access Management, Single Sign On and Authentication taking place on July 25th or visit the 2019 Thales Access Management Index.
The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.
1 The 2019 Access Management Index, is a survey of 1050 executives in 11 countries with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne , commissioned by Thales.
Thales, Media Relations
+33 (0)1 57 77 91 58
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu